BARCELONA SEPTEMBER 20-21
AUDITORIUM. BELLVITGE UNIVERSITY HOSPITAL
An international meeting to introduce Oncobell, a new cancer research program within the Bellvitge Biomedical Research Institute (IDIBELL).
0000
09.00h – 09.45h
REGISTRATION
09.45h – 10.00h
WELCOME
10.00h – 10.50h
KEYNOTE LECTURE:
Chaired by: Ramón Salazar, IDIBELL, Barcelona, Spain.
Exploiting vulnerabilities of drug-resistant cancer.
René Bernards, NKI, Amsterdam, Netherlands.
11.00h – 11.20h
COFFEE BREAK
11.20h – 13.40h
BRISTOL-MYERS SQUIBB SESSION: CLINICAL RESEARCH
Chaired by: Josep Mª Piulats, IDIBELL, Barcelona, Spain.
The Impact of the Check Point Inhibition Strategies in the Treatment of Hematological Malignancies.
Eva Domingo-Domènech, IDIBELL, Barcelona, Spain.
Harnessing the personalized antitumor T-cell response to treat cancer.
Alena Gros, VHIO, Barcelona, Spain.
Potential and limitations of oncolytic adenoviruses.
Ramón Alemany, IDIBELL, Barcelona, Spain.
Developping a CART19 under «academic conditions». How far can we drive it?
Manel Juan, Hospital Clínic, Barcelona, Spain.
13.40h – 14.40h
LUNCH
14.40h – 17.00h
GENETICS OF CANCER
Chaired by: Laura Valle, IDIBELL, Barcelona, Spain.
Genetic susceptibility of colorectal cancer.
Victor Moreno, IDIBELL, Barcelona, Spain.
Clinical impact of genomic studies in chronic lymphocytic leukemia.
Elías Campo, IDIBAPS, Barcelona, Spain.
The challenge of interpreting variants of unknown significance.
Gabriel Capellà, IDIBELL, Barcelona, Spain.
Cross-species analysis of gene regulatory networks in metastatic prostate cancer.
Àlvaro Aytes, IDIBELL, Barcelona, Spain.
0000
09.00h – 11.20h
TARGETING OF SIGNALING PATHWAYS
Chaired by: Cristina Muñoz-Pinedo, IDIBELL, Barcelona, Spain.
Insights into mechanisms of prostate cancer resistance.
Mark Rubin, Bern Univ, Switzerland.
Immune evasion and metastasis in colorectal cancer.
Eduard Batlle, IRBB, Barcelona, Spain.
The rationale for targeting TGF-beta in hepatocellular carcinoma.
Isabel Fabregat, IDIBELL, Barcelona, Spain.
Targeting the IRBC in c-Myc driven tumors.
George Thomas, IDIBELL, Barcelona, Spain.
11.20h – 12.20h
POSTER SESSION and COFFE BREAK
12.20h – 13.20h
POSTERS HIGHLIGHTS
The immune response: radio- and immuno-therapy. Miguel Angel Berenguer, IDIBELL.
Liquid Biopsis. Gabriel Capellà, IDIBELL.
Experimental therapeutics. Ernest Nadal, IDIBELL.
Other topics will be considered.
13.20h – 14.10h
KEYNOTE LECTURE:
Chaired by Oriol Casanovas, IDIELL, Barcelona, Spain.
Epigenetic signaling pathways controlling invasion and metastasis.
Douglas Hanahan, ISREC, Lausanne, Switzerland.
14.10h – 15.00h
LUNCH
15.00h – 16.45h
DRUG RESISTANCE AND MICROENVIRONMENT
Chaired by: Mariona Graupera, IDIBELL.
LIF and the innate immune response. Linking embryology and cancer.
Joan Seoane, VHIO, Barcelona, Spain.
Resistance to Antiangiogenic Therapies by Metabolic Escape via Nucleotide Catabolism.
Oriol Casanovas, IDIBELL, Barcelona, Spain.
Understanding sarcomas: a path to a successful treatment.
Òscar Martinez-Tirado, IDIBELL, Barcelona, Spain.
16.45h – 17.35h
RAMÓN ARECES LECTURE:
Chaire by George Thomas, IDIBELL, Barcelona, Spain.
Cell Signaling by Receptor Tyrosine Kinases; From Basic Principles to Cancer Therapy.
Joseph Schlessinger, Yale University, New Haven, USA.
17.35h – 17.45h
CLOSING REMARKS
0000